This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Proactive: Race Oncology On Track For Clinical Trials Following ‘Excellent’ RC220 Bisantrene Safety And Toxicology Results
Race CEO Dr Daniel Tillett spoke with Johnathan Jackson at Proactive about the completion of GLP studies for RC220 bisantrene.
Dr Tillett noted that the studies demonstrated excellent safety profile for RC220 bisantrene. It gives the new formulation of bisantrene IP and protection, moves the drug closer to human clinical trial, and marks a starting dose for the upcoming Phase 1 trial.
Read the full article here.